First Wave BioPharma to Participate in BIO Partnering @JPM During “J.P. Morgan Week 2024” 

Rhea-AI Summary

First Wave BioPharma, Inc. (NASDAQ: FWBI) is participating in BIO Partnering @JPM from January 8-12, 2024, in San Francisco. The company will conduct one-on-one meetings with investors and pharmaceutical companies to showcase its business and clinical development strategy.

BOCA RATON, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the company will participate in BIO Partnering @JPM being held January 8-12, 2024 in San Francisco.

Details of the events are as follows:

Event:	BIO Partnering @JPM
Date:	January 8-12, 2024
Location:	San Francisco Marriott Marquis, 780 Mission St, San Francisco, CA
Registration:	https://bpjw.bio.org/registration

During the conference, members of the First Wave BioPharma management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones. 

About First Wave BioPharma, Inc. 
First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple Phase 2 clinical stage programs built around three proprietary technologies – the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency; Capeserod, a selective 5-HT4 receptor partial agonist which First Wave is developing for gastrointestinal (GI) indications; and Niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

For more information: 
First Wave BioPharma, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Phone: (561) 589-7020
info@firstwavebio.com 

Media contact: 
Tiberend Strategic Advisors, Inc. 
David Schemelia 
(609) 468-9325 
dschemelia@tiberend.com 

FAQ

What is the event First Wave BioPharma, Inc. (NASDAQ: FWBI) is participating in?

The company is participating in BIO Partnering @JPM from January 8-12, 2024, in San Francisco.

Where is the event being held?

The event will take place at San Francisco Marriott Marquis, 780 Mission St, San Francisco, CA.

What will the company do during the event?

Members of the management team will conduct one-on-one meetings with registered investors and pharmaceutical companies to showcase the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.